D
Interpace Biosciences, Inc.
IDXG
$1.25
$0.00280.23%
D
Sell
2/10/2025Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to D+ from C- on 2/10/2025 due to a decline in the total return index and volatility index.
Interpace Biosciences, Inc. (IDXG) was downgraded to D+ from C- on 2/10/2025 due to a decline in the total return index and volatility index.
C
Hold
11/15/2024Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to C- from C on 11/15/2024 due to a noticeable decline in the growth index and solvency index. Earnings per share declined from $0.4712 to $0.2915, debt to equity increased from -0.12 to -0.1, and EBIT declined 15.6% from $2.26M to $1.91M.
Interpace Biosciences, Inc. (IDXG) was downgraded to C- from C on 11/15/2024 due to a noticeable decline in the growth index and solvency index. Earnings per share declined from $0.4712 to $0.2915, debt to equity increased from -0.12 to -0.1, and EBIT declined 15.6% from $2.26M to $1.91M.
C
Hold
11/12/2024Upgraded
Interpace Biosciences, Inc. (IDXG) was upgraded to C from C- on 11/12/2024 due to a large increase in the total return index and volatility index.
Interpace Biosciences, Inc. (IDXG) was upgraded to C from C- on 11/12/2024 due to a large increase in the total return index and volatility index.
C
Hold
10/8/2024Upgraded
Interpace Biosciences, Inc. (IDXG) was upgraded to C- from D+ on 10/8/2024 due to an increase in the volatility index and total return index.
Interpace Biosciences, Inc. (IDXG) was upgraded to C- from D+ on 10/8/2024 due to an increase in the volatility index and total return index.
D
Sell
8/15/2024Upgraded
Interpace Biosciences, Inc. (IDXG) was upgraded to D+ from D on 8/15/2024 due to a major increase in the growth index, valuation index and volatility index. Operating cash flow increased 2,520.69% from -$58 to $1.4M, earnings per share increased from $0.1063 to $0.4712, and EBIT increased 158.24% from $874 to $2.26M.
Interpace Biosciences, Inc. (IDXG) was upgraded to D+ from D on 8/15/2024 due to a major increase in the growth index, valuation index and volatility index. Operating cash flow increased 2,520.69% from -$58 to $1.4M, earnings per share increased from $0.1063 to $0.4712, and EBIT increased 158.24% from $874 to $2.26M.
D
Sell
8/1/2024Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to D from D+ on 8/1/2024 due to a large decline in the growth index, total return index and solvency index. Operating cash flow declined 105.09% from $1.14M to -$58, earnings per share declined from $0.1984 to $0.1063, and EBIT declined 33.79% from $1.32M to $874.
Interpace Biosciences, Inc. (IDXG) was downgraded to D from D+ on 8/1/2024 due to a large decline in the growth index, total return index and solvency index. Operating cash flow declined 105.09% from $1.14M to -$58, earnings per share declined from $0.1984 to $0.1063, and EBIT declined 33.79% from $1.32M to $874.
D
Sell
4/11/2024Upgraded
Interpace Biosciences, Inc. (IDXG) was upgraded to D+ from E+ on 4/11/2024 due to a significant increase in the valuation index, efficiency index and growth index. EBIT increased 8,350% from -$16 to $1.32M, net income increased 244.95% from -$614 to $890, and earnings per share increased from -$0.1422 to $0.1984.
Interpace Biosciences, Inc. (IDXG) was upgraded to D+ from E+ on 4/11/2024 due to a significant increase in the valuation index, efficiency index and growth index. EBIT increased 8,350% from -$16 to $1.32M, net income increased 244.95% from -$614 to $890, and earnings per share increased from -$0.1422 to $0.1984.
E
Sell
12/15/2023Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to E+ from D- on 12/15/2023 due to a decline in the volatility index and total return index.
Interpace Biosciences, Inc. (IDXG) was downgraded to E+ from D- on 12/15/2023 due to a decline in the volatility index and total return index.
D
Sell
11/30/2023Upgraded
Interpace Biosciences, Inc. (IDXG) was upgraded to D- from E+ on 11/30/2023 due to an increase in the volatility index.
Interpace Biosciences, Inc. (IDXG) was upgraded to D- from E+ on 11/30/2023 due to an increase in the volatility index.
E
Sell
11/13/2023Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to E+ from D- on 11/13/2023 due to a noticeable decline in the growth index, volatility index and total return index. Earnings per share declined from $0.039 to -$0.1422, EBIT declined 101.92% from $832 to -$16, and total revenue declined 17.67% from $11.03M to $9.08M.
Interpace Biosciences, Inc. (IDXG) was downgraded to E+ from D- on 11/13/2023 due to a noticeable decline in the growth index, volatility index and total return index. Earnings per share declined from $0.039 to -$0.1422, EBIT declined 101.92% from $832 to -$16, and total revenue declined 17.67% from $11.03M to $9.08M.
D
Sell
11/8/2023Upgraded
Interpace Biosciences, Inc. (IDXG) was upgraded to D- from E+ on 11/8/2023 due to an increase in the volatility index.
Interpace Biosciences, Inc. (IDXG) was upgraded to D- from E+ on 11/8/2023 due to an increase in the volatility index.
E
Sell
9/26/2023Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to E+ from D- on 9/26/2023 due to a noticeable decline in the growth index, volatility index and total return index. Operating cash flow declined 63.72% from $1.13M to $411, and earnings per share declined from $0.0815 to $0.039.
Interpace Biosciences, Inc. (IDXG) was downgraded to E+ from D- on 9/26/2023 due to a noticeable decline in the growth index, volatility index and total return index. Operating cash flow declined 63.72% from $1.13M to $411, and earnings per share declined from $0.0815 to $0.039.
D
Sell
6/30/2023Upgraded
Interpace Biosciences, Inc. (IDXG) was upgraded to D- from E+ on 6/30/2023 due to an increase in the volatility index and total return index.
Interpace Biosciences, Inc. (IDXG) was upgraded to D- from E+ on 6/30/2023 due to an increase in the volatility index and total return index.
E
Sell
6/12/2023Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to E+ from D- on 6/12/2023 due to a decline in the volatility index.
Interpace Biosciences, Inc. (IDXG) was downgraded to E+ from D- on 6/12/2023 due to a decline in the volatility index.
D
Sell
5/25/2023Upgraded
Interpace Biosciences, Inc. (IDXG) was upgraded to D- from E+ on 5/25/2023 due to a major increase in the growth index, total return index and volatility index. Operating cash flow increased 510.51% from -$276 to $1.13M, EBIT increased 375.35% from $142 to $675, and earnings per share increased from -$0.3669 to $0.0815.
Interpace Biosciences, Inc. (IDXG) was upgraded to D- from E+ on 5/25/2023 due to a major increase in the growth index, total return index and volatility index. Operating cash flow increased 510.51% from -$276 to $1.13M, EBIT increased 375.35% from $142 to $675, and earnings per share increased from -$0.3669 to $0.0815.
E
Sell
3/14/2023Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to E+ from D- on 03/14/2023.
Interpace Biosciences, Inc. (IDXG) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
Interpace Biosciences, Inc. (IDXG) was upgraded to D- from E+ on 02/23/2023.
Interpace Biosciences, Inc. (IDXG) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to E+ from D- on 2/8/2023 due to a decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.9314 to -$3.3537, and operating cash flow declined 11.17% from -$2.92M to -$3.24M.
Interpace Biosciences, Inc. (IDXG) was downgraded to E+ from D- on 2/8/2023 due to a decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.9314 to -$3.3537, and operating cash flow declined 11.17% from -$2.92M to -$3.24M.
D
Sell
10/28/2022Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to D- from D on 10/28/2022 due to a noticeable decline in the growth index, total return index and volatility index. Operating cash flow declined 132.7% from -$1.25M to -$2.92M, EBIT declined 104.41% from -$1.95M to -$3.98M, and earnings per share declined from -$0.534 to -$0.9323.
Interpace Biosciences, Inc. (IDXG) was downgraded to D- from D on 10/28/2022 due to a noticeable decline in the growth index, total return index and volatility index. Operating cash flow declined 132.7% from -$1.25M to -$2.92M, EBIT declined 104.41% from -$1.95M to -$3.98M, and earnings per share declined from -$0.534 to -$0.9323.
D
Sell
5/5/2022Upgraded
Interpace Biosciences, Inc. (IDXG) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
Interpace Biosciences, Inc. (IDXG) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to D- from D on 4/20/2022 due to a major decline in the total return index, volatility index and solvency index.
Interpace Biosciences, Inc. (IDXG) was downgraded to D- from D on 4/20/2022 due to a major decline in the total return index, volatility index and solvency index.
D
Sell
11/11/2021Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to D from D+ on 11/11/2021 due to a large decline in the growth index, solvency index and total return index. EBIT declined 77.64% from -$2.05M to -$3.64M, debt to equity increased from -0.24 to -0.2, and total revenue declined 15.09% from $11.16M to $9.47M.
Interpace Biosciences, Inc. (IDXG) was downgraded to D from D+ on 11/11/2021 due to a large decline in the growth index, solvency index and total return index. EBIT declined 77.64% from -$2.05M to -$3.64M, debt to equity increased from -0.24 to -0.2, and total revenue declined 15.09% from $11.16M to $9.47M.
D
Sell
11/9/2021Upgraded
Interpace Biosciences, Inc. (IDXG) was upgraded to D+ from D- on 11/09/2021.
Interpace Biosciences, Inc. (IDXG) was upgraded to D+ from D- on 11/09/2021.
D
Sell
11/8/2021Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to D- from D+ on 11/8/2021 due to a noticeable decline in the growth index and solvency index. The quick ratio declined from 0.52 to 0.49.
Interpace Biosciences, Inc. (IDXG) was downgraded to D- from D+ on 11/8/2021 due to a noticeable decline in the growth index and solvency index. The quick ratio declined from 0.52 to 0.49.
D
Sell
5/25/2021Upgraded
Interpace Biosciences, Inc. (IDXG) was upgraded to D+ from D on 5/25/2021 due to a significant increase in the growth index, total return index and volatility index. EBIT increased 69.59% from -$8.43M to -$2.56M, earnings per share increased from -$2.0221 to -$1.0332, and total revenue increased 1.94% from $9.65M to $9.83M.
Interpace Biosciences, Inc. (IDXG) was upgraded to D+ from D on 5/25/2021 due to a significant increase in the growth index, total return index and volatility index. EBIT increased 69.59% from -$8.43M to -$2.56M, earnings per share increased from -$2.0221 to -$1.0332, and total revenue increased 1.94% from $9.65M to $9.83M.
D
Sell
1/25/2021Upgraded
Interpace Biosciences, Inc. (IDXG) was upgraded to D from D- on 1/25/2021 due to an increase in the volatility index and growth index. Total revenue increased 51.45% from $5.45M to $8.25M.
Interpace Biosciences, Inc. (IDXG) was upgraded to D from D- on 1/25/2021 due to an increase in the volatility index and growth index. Total revenue increased 51.45% from $5.45M to $8.25M.
D
Sell
10/9/2020Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to D- from D on 10/9/2020 due to a decline in the volatility index and total return index.
Interpace Biosciences, Inc. (IDXG) was downgraded to D- from D on 10/9/2020 due to a decline in the volatility index and total return index.
D
Sell
8/21/2020Upgraded
Interpace Biosciences, Inc. (IDXG) was upgraded to D from D- on 8/21/2020 due to an increase in the valuation index and total return index.
Interpace Biosciences, Inc. (IDXG) was upgraded to D from D- on 8/21/2020 due to an increase in the valuation index and total return index.
D
Sell
8/6/2020Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to D- from D on 8/6/2020 due to a decline in the volatility index and valuation index.
Interpace Biosciences, Inc. (IDXG) was downgraded to D- from D on 8/6/2020 due to a decline in the volatility index and valuation index.
D
Sell
7/20/2020Upgraded
Interpace Biosciences, Inc. (IDXG) was upgraded to D from D- on 7/20/2020 due to an increase in the volatility index and total return index.
Interpace Biosciences, Inc. (IDXG) was upgraded to D from D- on 7/20/2020 due to an increase in the volatility index and total return index.
D
Sell
7/1/2020Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to D- from D on 7/1/2020 due to a decline in the volatility index.
Interpace Biosciences, Inc. (IDXG) was downgraded to D- from D on 7/1/2020 due to a decline in the volatility index.
D
Sell
6/26/2020Upgraded
Interpace Biosciences, Inc. (IDXG) was upgraded to D from D- on 6/26/2020 due to an increase in the volatility index.
Interpace Biosciences, Inc. (IDXG) was upgraded to D from D- on 6/26/2020 due to an increase in the volatility index.
D
Sell
6/10/2020Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to D- from D on 6/10/2020 due to a decline in the total return index and volatility index.
Interpace Biosciences, Inc. (IDXG) was downgraded to D- from D on 6/10/2020 due to a decline in the total return index and volatility index.
D
Sell
5/8/2020Upgraded
Interpace Biosciences, Inc. (IDXG) was upgraded to D from D- on 5/8/2020 due to an increase in the growth index.
Interpace Biosciences, Inc. (IDXG) was upgraded to D from D- on 5/8/2020 due to an increase in the growth index.
D
Sell
4/23/2020Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to D- from D on 4/23/2020 due to a noticeable decline in the solvency index, efficiency index and growth index. EBIT declined 75.16% from -$6.21M to -$10.88M, earnings per share declined from -$1.9471 to -$2.9056, and total revenue declined 47.26% from $7.73M to $4.07M.
Interpace Biosciences, Inc. (IDXG) was downgraded to D- from D on 4/23/2020 due to a noticeable decline in the solvency index, efficiency index and growth index. EBIT declined 75.16% from -$6.21M to -$10.88M, earnings per share declined from -$1.9471 to -$2.9056, and total revenue declined 47.26% from $7.73M to $4.07M.
D
Sell
1/29/2020Upgraded
Interpace Biosciences, Inc. (IDXG) was upgraded to D from D- on 1/29/2020 due to an increase in the valuation index and volatility index.
Interpace Biosciences, Inc. (IDXG) was upgraded to D from D- on 1/29/2020 due to an increase in the valuation index and volatility index.
D
Sell
1/14/2020Downgrade
Interpace Biosciences, Inc. (IDXG) was downgraded to D- from D on 1/14/2020 due to a large decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.02 to 0.52, EBIT declined 56.53% from -$3.97M to -$6.21M, and earnings per share declined from -$0.1383 to -$0.1947.
Interpace Biosciences, Inc. (IDXG) was downgraded to D- from D on 1/14/2020 due to a large decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.02 to 0.52, EBIT declined 56.53% from -$3.97M to -$6.21M, and earnings per share declined from -$0.1383 to -$0.1947.
D
Sell
3/29/2019Upgraded
Interpace Diagnostics Group, Inc. (IDXG) was upgraded to D from D- on 3/29/2019 due to a large increase in the growth index, efficiency index and valuation index. Total revenue increased 1.41% from $5.75M to $5.83M.
Interpace Diagnostics Group, Inc. (IDXG) was upgraded to D from D- on 3/29/2019 due to a large increase in the growth index, efficiency index and valuation index. Total revenue increased 1.41% from $5.75M to $5.83M.
D
Sell
11/21/2018Downgrade
Interpace Diagnostics Group, Inc. (IDXG) was downgraded to D- from D on 11/21/2018 due to a substantial decline in the growth index, efficiency index and solvency index. Net income declined 58.69% from -$1.92M to -$3.04M, earnings per share declined from -$0.0716 to -$0.1112, and EBIT declined 29.87% from -$1.9M to -$2.47M.
Interpace Diagnostics Group, Inc. (IDXG) was downgraded to D- from D on 11/21/2018 due to a substantial decline in the growth index, efficiency index and solvency index. Net income declined 58.69% from -$1.92M to -$3.04M, earnings per share declined from -$0.0716 to -$0.1112, and EBIT declined 29.87% from -$1.9M to -$2.47M.
D
Sell
8/14/2018Upgraded
Interpace Diagnostics Group, Inc. (IDXG) was upgraded to D from D- on 8/14/2018 due to a large increase in the growth index, efficiency index and volatility index. EBIT increased 41.56% from -$3.25M to -$1.9M, net income increased 39.96% from -$3.19M to -$1.92M, and earnings per share increased from -$0.1146 to -$0.0716.
Interpace Diagnostics Group, Inc. (IDXG) was upgraded to D from D- on 8/14/2018 due to a large increase in the growth index, efficiency index and volatility index. EBIT increased 41.56% from -$3.25M to -$1.9M, net income increased 39.96% from -$3.19M to -$1.92M, and earnings per share increased from -$0.1146 to -$0.0716.
D
Sell
5/17/2018Downgrade
Interpace Diagnostics Group, Inc. (IDXG) was downgraded to D- from D on 5/17/2018 due to a significant decline in the valuation index, efficiency index and volatility index. Total capital declined 0.26% from $39.87M to $39.77M.
Interpace Diagnostics Group, Inc. (IDXG) was downgraded to D- from D on 5/17/2018 due to a significant decline in the valuation index, efficiency index and volatility index. Total capital declined 0.26% from $39.87M to $39.77M.
D
Sell
11/14/2017Upgraded
Interpace Diagnostics Group, Inc. (IDXG) was upgraded to D from D- on 11/14/2017 due to a significant increase in the valuation index, solvency index and efficiency index. Net income increased 47.42% from -$6.31M to -$3.32M, the quick ratio increased from 1.59 to 1.75, and total capital increased 0.1% from $36.34M to $36.38M.
Interpace Diagnostics Group, Inc. (IDXG) was upgraded to D from D- on 11/14/2017 due to a significant increase in the valuation index, solvency index and efficiency index. Net income increased 47.42% from -$6.31M to -$3.32M, the quick ratio increased from 1.59 to 1.75, and total capital increased 0.1% from $36.34M to $36.38M.
D
Sell
3/11/2016Downgrade
Interpace Diagnostics Group, Inc. (IDXG) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index, solvency index and total return index. Debt to equity increased from 2.69 to 4.76, and the quick ratio declined from 0.95 to 0.85.
Interpace Diagnostics Group, Inc. (IDXG) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index, solvency index and total return index. Debt to equity increased from 2.69 to 4.76, and the quick ratio declined from 0.95 to 0.85.
D
Sell
8/12/2014Downgrade
PDI, Inc. (PDII) was downgraded to D from D+ on 8/12/2014 due to a decline in the growth index.
PDI, Inc. (PDII) was downgraded to D from D+ on 8/12/2014 due to a decline in the growth index.
D
Sell
5/16/2014Upgraded
PDI, Inc. (PDII) was upgraded to D+ from D on 5/16/2014 due to an increase in the efficiency index, growth index and solvency index. Operating cash flow increased 72.39% from -$3.75M to -$6.46M.
PDI, Inc. (PDII) was upgraded to D+ from D on 5/16/2014 due to an increase in the efficiency index, growth index and solvency index. Operating cash flow increased 72.39% from -$3.75M to -$6.46M.
OTC PK
03/07/2025 11:33AM Eastern
Quotes delayed
